In this study, using a classical murine model of allergic airway inflammation (AAI) that mimics human asthma, we demonstrated that the SGLT2 inhibitor empagliflozin effectively suppresses OVA-induced airway inflammation in MGO-exposed mice, as evidenced by the marked reductions in eosinophil infiltration, mucus production and collagen deposition, as well as by the reduced levels of IgE, IL-4, IL-5, IL-13, eotaxin, and TNF-α in the lungs. Here, IL13 is linked to asthma.